Markets
Scholar Rock Stock Plunges 7% After Management Tempers Expectations For Early Sales Surge
Most early ISEMBYLD enrollees are expected to start infusions in 2027, management said, after the first patients began in October.
SRRK
Scholar Rock Holding (SRRK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Scholar Rock Expects Most Early ISEMBYLD Patients To Wait Until 2027 For Infusions
Insurance reviews and hospital approvals are slowing treatment starts, while management expects steady additions rather than a sales burst.
SEC Filings
Scholar Rock Secures $205 Million Voucher Deal To Fund Its Move Into Drug Sales
Initial ISEMBYLD shipments brought in $0.6 million, with first patient infusions in October and overseas regulatory reviews underway.